Ten structural accounts of how the Gulf biotechnology economy works.
Sovereign balance sheets, announced partnership values and venture rounds are three different instruments. Told apart, they show a market building faster in manufacturing than in equity.
Companies and platforms across six markets, a 62-strong Saudi accelerator cohort and a university spinout already selling abroad. Intellectual property is the next frontier.
Eleven translation programmes now run across the region, from a home-grown CAR-T to gene therapy delivered in Doha. The next move is owning more of what gets tested.
An operating biologics facility, insulin lines building toward 2027 and vaccine agreements with three of the largest manufacturers in the world. The build is under way, and commissioning and output are the next milestones to track.
The commercial unit in Abu Dhabi is the dataset. That changes who the counterparties are, with value exchanged as data and capability rather than cash.
The Gulf's genomics programmes are among the largest in the world by enrolment. Converting that enrolment into published analysis is the next stage.
WHO Maturity Level 4 covers medicines and vaccines in Saudi Arabia. For four of the six states, published review timelines are the next milestone.
Shared benches in Abu Dhabi, an accelerator with the drug regulator inside it and a 62-company cohort in Riyadh. The infrastructure went in first, on purpose.
KFSHRC, M42, Qatar Foundation and Lifera. Concentration of this degree gives partners a clear counterparty in each market and sets the pace of the build.
Two completed acquisitions in Britain, laboratory diagnostics among them, and a state manufacturer operating on three continents. The next milestone is Gulf technology going the other way.
Distributor, local marketing authorisation holder or subsidiary. The choice decides who owns the registration, the pricing file and the customer.
Federal registration and emirate-level licensing are separate processes. Treating them separately is the first step to a clean entry.
One regulator, one representative requirement and a reference-approval precondition for most devices.
Biotechnology, diagnostics, capital, regulation, science and manufacturing across the six Gulf markets. Every item is selected for its significance and carries a direct source and a verification date.